Loading patent…
AssigneeAdvinus Therapeutics Private Limited
InventorsDinesh Barawkar, Sujay Basu, Vidya Ramdas, Venkata Poornapragnacharyulu Palle, Yogesh Waman, Meena Patel, Anil Panmand
Estimating the term…
The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
A compound which is
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
Purines, e.g. adenine: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Phosphorus compounds: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
About 4 years 10 months of term left · ends 9 Sep 2031 (estimated)
This is a national stage application of PCT Application No. PCT/IN2011/000620, filed on Sep. 9, 2011, which claims priority to India Patent Application No. 2671/CHE/2010, filed on Sep. 13, 2010, the entire contents of each of which are incorporated by reference in their entireties.
The present disclosure relates to parine compounds or its tautomers, polymorphs, stereoisomers, solvates or pharmaceutically acceptable salts thereof, as prodrugs of A2B adenosine receptor antagonists, and to their use in treating mammals for various disease states, such as gastrointestinal disorders, immunological disorders, hypersensitivity disorders, neurological disorders, and cardiovascular diseases due to both cellular hyperproliferation and apoptosis, and the like. The disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
Adenosine is known to be an endogenous modulator of a number of physiological functions and these are mediated by the interaction with different membrane specific receptors which belong to the family of receptors coupled with G proteins. Adenosine exerts effects in cardiovascular, central nervous, respiratory systems, kidney, adipose and platelets. Recent advances in molecular biolog) coupled with several pharmacological studies have lead to identification of at least four subtypes of adenosine receptors, A1, A2B, A2b and A3. The A1 and A3 receptors down-regulate cellular cAMP levels through their coupling to G protein, which inhibit adenylate cyclase. In contrast, A2A and A2B receptors couple to G protein that activate adenylate cyclase and increase intracellular levels of cAMP.
Definitions
In the structural formulae given herein and throughout the present disclosure, the following terms have the indicated meaning, unless specifically stated otherwise.
The term “optionally substituted” as used herein means that the group in question is either unsubstituted or substituted with one or more of the substituents specified. When the group in question is substituted with more than one substituent, the substituent may be same or different.